Cargando…

CA 19-9 serum levels in patients with end-stage idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs): Correlation with functional decline

Idiopathic pulmonary fibrosis presents a progressive and heterogeneous functional decline. CA 19-9 has been proposed as biomarker to predict disease course, but its role remains unclear. We assessed CA 19-9 levels and clinical data in end-stage ILD patients (48 IPF and 20 non-IPF ILD) evaluated for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balestro, Elisabetta, Castelli, Gioele, Bernardinello, Nicol, Cocconcelli, Elisabetta, Biondini, Davide, Fracasso, Federico, Rea, Federico, Saetta, Marina, Baraldo, Simonetta, Spagnolo, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521048/ https://www.ncbi.nlm.nih.gov/pubmed/32969271 http://dx.doi.org/10.1177/1479973120958428

Ejemplares similares

Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
por: Biondini, Davide, et al.
Publicado: (2021)

Radiological Assessment in Idiopathic Pulmonary Fibrosis (IPF) Patients According to MUC5B Polymorphism
por: Cocconcelli, Elisabetta, et al.
Publicado: (2022)

The Role of the Lung’s Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis
por: Spagnolo, Paolo, et al.
Publicado: (2019)

Molecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis
por: Cocconcelli, Elisabetta, et al.
Publicado: (2023)

Idiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible
por: Balestro, Elisabetta, et al.
Publicado: (2019)

High-Resolution Computed Tomography (HRCT) Reflects Disease Progression in Patients with Idiopathic Pulmonary Fibrosis (IPF): Relationship with Lung Pathology
por: Cocconcelli, Elisabetta, et al.
Publicado: (2019)

Clinical Features and Chest Imaging as Predictors of Intensity of Care in Patients with COVID-19
por: Cocconcelli, Elisabetta, et al.
Publicado: (2020)

Characteristics and Prognostic Factors of Pulmonary Fibrosis After COVID-19 Pneumonia
por: Cocconcelli, Elisabetta, et al.
Publicado: (2022)

Predictors of pulmonary sequelae after COVID-19 pneumonia: A 12-month follow-up study
por: Bernardinello, Nicol, et al.
Publicado: (2023)

CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
por: Zanatta, Elisabetta, et al.
Publicado: (2023)

Brief communication: Chest radiography score in young COVID-19 patients: Does one size fit all?
por: Castelli, Gioele, et al.
Publicado: (2022)

Disease Severity and Prognosis of SARS-CoV-2 Infection in Hospitalized Patients Is Not Associated With Viral Load in Nasopharyngeal Swab
por: Cocconcelli, Elisabetta, et al.
Publicado: (2021)

Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis
por: Balestro, Elisabetta, et al.
Publicado: (2016)

Pleural clinic: where thoracic ultrasound meets respiratory medicine
por: Tinè, Mariaenrica, et al.
Publicado: (2023)

Pulmonary Sarcoidosis: Diagnosis and Differential Diagnosis
por: Bernardinello, Nicol, et al.
Publicado: (2021)

Heart Failure is Highly Prevalent and Difficult to Diagnose in Severe Exacerbations of COPD Presenting to the Emergency Department
por: Tinè, Mariaenrica, et al.
Publicado: (2020)

Chronic Bronchitis Affects Outcomes in Smokers without Chronic Obstructive Pulmonary Disease (COPD)
por: Casara, Alvise, et al.
Publicado: (2022)

Critical Review of the Evolution of Extracellular Vesicles’ Knowledge: From 1946 to Today
por: Bazzan, Erica, et al.
Publicado: (2021)

The Role of Bronchoscopy in the Diagnosis and Management of Patients with SARS-Cov-2 Infection
por: Biondini, Davide, et al.
Publicado: (2021)

Macrophages-derived Factor XIII links coagulation to inflammation in COPD
por: Bazzan, Erica, et al.
Publicado: (2023)

Serum Progranulin Level Might Differentiate Non-IPF ILD from IPF
por: Tóth, Nóra Melinda, et al.
Publicado: (2023)

Dual polarization of human alveolar macrophages progressively increases with smoking and COPD severity
por: Bazzan, Erica, et al.
Publicado: (2017)

ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF
por: Durheim, Michael T, et al.
Publicado: (2020)

High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment
por: Balestro, Elisabetta, et al.
Publicado: (2019)

Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort
por: Zanatta, Elisabetta, et al.
Publicado: (2023)

Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis
por: Biondini, Davide, et al.
Publicado: (2018)

Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management
por: De Zorzi, Elena, et al.
Publicado: (2022)

Exome Sequencing Reveals Immune Genes as Susceptibility Modifiers in Individuals with α(1)-Antitrypsin Deficiency
por: Rigobello, Chiara, et al.
Publicado: (2019)

The Challenge of Diagnosing and Managing Pulmonary Arterial Hypertension in Systemic Sclerosis with Interstitial Lung Disease
por: Zanatta, Elisabetta, et al.
Publicado: (2022)

Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
por: de Andrade, Joao A., et al.
Publicado: (2022)

Exploring the common pathophysiological links between IPF, SSc-ILD and post-COVID fibrosis
por: Swarnakar, Rajesh, et al.
Publicado: (2022)

Early Airway Pathological Changes in Children: New Insights into the Natural History of Wheezing
por: Bonato, Matteo, et al.
Publicado: (2019)

Pulmonary fibrosis secondary to COVID-19: a call to arms?
por: Spagnolo, Paolo, et al.
Publicado: (2020)

ChILD – Children's interstitial lung disease
Publicado: (2018)

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
por: Corte, Tamera J, et al.
Publicado: (2021)

Interstitial lung disease (ILD) in India: Insights and lessons from the prospective, landmark ILD-India registry
por: Raghu, Ganesh, et al.
Publicado: (2016)

Impact of progressive fibrosing interstitial lung disease (ILD) in ILD patients complicated with secondary spontaneous pneumothorax
por: Yamakawa, Hideaki, et al.
Publicado: (2021)

Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg)
por: Krauss, Ekaterina, et al.
Publicado: (2020)

IPF - Idiopathic Pulmonary Fibrosis
Publicado: (2019)

Cognitive and Psychological Sequelae of COVID-19: Age Differences in Facing the Pandemic
por: Devita, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p706ha5lveql86bh0lc0lrgl4h